PDC*line Pharma

PDCline Pharma develops off-the-shelf cancer immunotherapy targeting lung cancer and neoantigens.

Overview

PDC*line Pharma is an innovative Belgian-French biotechnology company founded in April 2014 as a spin-off of the Établissement Français du Sang (EFS), dedicated to developing antigen-specific cancer immunotherapies. The company operates research and development centers in Liège, Belgium and Grenoble, France.

Something wrong or missing? Send an update. Fixed within 24 hours.